1.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
2.
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Friedman RC, Farh KK, Burge CB, et al:
Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Hernando E: microRNAs and cancer: role in
tumorigenesis, patient classification and therapy. Clin Transl
Oncol. 9:155–160. 2007. View Article : Google Scholar
|
7.
|
Negrini M, Ferracin M, Sabbioni S, et al:
MicroRNAs in human cancer: from research to therapy. J Cell Sci.
120:1833–1840. 2007. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Chen YL, Huang ZQ, Zhou NX, et al:
Clinical analysis of 110 patients with primary gallbladder
carcinoma. Zhonghua Zhong Liu Za Zhi. 29:704–706. 2007.(In
Chinese).
|
9.
|
Bao B, Ali S, Banerjee S, et al: Curcumin
analogue CDF inhibits pancreatic tumor growth by switching on
suppressor microRNAs and attenuating EZH2 expression. Cancer Res.
72:335–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Lu J, He ML, Wang L, et al: MiR-26a
inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma
through repression of EZH2. Cancer Res. 71:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
11.
|
Zhang B, Liu XX, He JR, et al:
Pathologically decreased miR-26a antagonizes apoptosis and
facilitates carcinogenesis by targeting MTDH and EZH2 in breast
cancer. Carcinogenesis. 32:2–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Dang X, Ma A, Yang L, et al: MicroRNA-26a
regulates tumorigenic properties of EZH2 in human lung carcinoma
cells. Cancer Genet. 205:113–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Kota J, Chivukula RR, O’Donnell KA, et al:
Therapeutic microRNA delivery suppresses tumorigenesis in a murine
liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Yang X, Liang L, Zhang XF, et al:
MicroRNA-26a suppresses tumor growth and metastasis of human
hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.
Hepatology. 58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Slaby O, Redova M, Poprach A, et al:
Identification of MicroRNAs associated with early relapse after
nephrectomy in renal cell carcinoma patients. Genes Chromosomes
Cancer. 51:707–716. 2012. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Xia X, Cheng A, Akinmade D, et al: The
N-terminal 24 amino acids of the p55 gamma regulatory subunit of
phosphoinositide 3-kinase binds Rb and induces cell cycle arrest.
Mol Cell Biol. 23:1717–1725. 2003. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Deng Q, Wang Q, Zong WY, et al: E2F8
contributes to human hepatocellular carcinoma via regulating cell
proliferation. Cancer Res. 70:782–791. 2010. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Sozzani R, Maggio C, Giordo R, et al: The
E2FD/DEL2 factor is a component of a regulatory network controlling
cell proliferation and development in Arabidopsis. Plant Mol Biol.
72:381–395. 2010. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Hazar-Rethinam M, Cameron SR, Dahler AL,
et al: Loss of E2F7 expression is an early event in squamous
differentiation and causes derepression of the key differentiation
activator Sp1. J Invest Dermatol. 131:1077–1084. 2011. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Sirma H, Kumar M, Meena JK, et al: The
promoter of human telomerase reverse transcriptase is activated
during liver regeneration and hepatocyte proliferation.
Gastroenterology. 141:326–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Li O, Vasudevan D, Davey CA, et al:
High-level expression of DNA architectural factor HMGA2 and its
association with nucleosomes in human embryonic stem cells.
Genesis. 44:523–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar
|
23.
|
Ashar HR, Chouinard RA Jr, Dokur M, et al:
In vivo modulation of HMGA2 expression. Biochim Biophys Acta.
1799:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Eda A, Tamura Y, Yoshida M, et al:
Systematic gene regulation involving miRNAs during neuronal
differentiation of mouse P19 embryonic carcinoma cell. Biochem
Biophys Res Commun. 388:648–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Ahmed KM, Tsai CY and Lee WH: Derepression
of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary
tumorigenesis. J Biol Chem. 285:4464–4471. 2010. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Cleynen I and Van de Ven WJ: The HMGA
proteins: a myriad of functions (Review). Int J Oncol. 32:289–305.
2008.PubMed/NCBI
|
27.
|
Sgarra R, Zammitti S, Lo Sardo A, et al:
HMGA molecular network: from transcriptional regulation to
chromatin remodeling. Biochim Biophys Acta. 1799:37–47. 2010.
View Article : Google Scholar : PubMed/NCBI
|
28.
|
Wang X, Liu X, Li AY, et al:
Overexpression of HMGA2 promotes metastasis and impacts survival of
colorectal cancers. Clin Cancer Res. 17:2570–2580. 2011. View Article : Google Scholar : PubMed/NCBI
|